Category Archives: Public Policy

Latest From Public Policy

San Francisco Business Times: Two JOBS Acts are better than one

scientist-eyedropper

Today, the San Francisco Business Times published an op-ed by OncoMed President and CEO Paul Hastings lauding the Jumpstart Our Business Startups Act (JOBS) Act for giving emerging biotech companies a much-needed boost. As Hastings points out, 80-plus companies will have gone public in the last two years with the help of the JOBS Act. As the biotech industry gathers in San Diego next month for the 2014 BIO International Convention, several CEOs in attendance will no Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

BIO Testifies at 21st Century Cures Hearing on PCAST

TheHill

Today, BIO’s Executive Vice President of Health Sara Radcliffe presented testimony to the U.S. House of Representatives Energy and Commerce Subcommittee on Health Hearing. The Hearing focused on the President’s Council of Advisors on Science and Technology (PCAST) Report on Drug Innovation and key issues related to the 21st Century Cures initiative to examine what steps the Committee can take to accelerate the pace of cures in America. Below is a summary: The Challenge of Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Recognizes the Work of Two Indiana Legislators

flag

Across the country state lawmakers are addressing the issue of biosimilars, lower-cost biologic medicines that stand to benefit severely ill patients combating complex and life threatening diseases. Indiana has been at the forefront of this important issue, and two Indiana state legislators, Representative Ed Clere and Senator Brandt Hershman, were particularly instrumental to the success of biosimilar legislation that was recently signed into law by Governor Mike Pence. Representative Ed Clere (District 72), is Chair Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

Nautilus v. Biosig, Baxter v. Fresenius and Limelight v. Akamai

Supreme Court

BIO weighed in on three Supreme Court cases in the last few months whose outcome could change the IP landscape for biotechnology companies. BIO’s amicus brief in Nautilus v. Biosig Instruments argues that the petitioner misrepresents the Federal Circuit’s definiteness test and seeks to litigate an issue not properly before this court.  Petitioner’s approach radically departs from established law and practice.  Finally the petitioner’s approach would destabilize the patent system as it would inject substantial Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Strongly Supports R&D Tax Credit Legislation

cells115x76

The House Ways and Means Committee posted the following message on its home page showing the support of several organizations, including BIO, for the American Research & Competitiveness Act (H.R. 4438): “Today, the National Association of Manufacturers, Chamber of Commerce, R&D Credit Coalition, and Biotechnology Industry Organization – representing thousands of small and large U.S. businesses – issued their support for H.R. 4438, a bipartisan, permanent extension of the research and development (R&D) tax credit. In their call for a permanent R&D Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,